Program
intismeran autogene
Also written as “Intismeran autogene”, “mRNA-4157” and “Intismeran”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Non-Muscle Invasive Bladder Neoplasms · Carcinoma, Renal Cell · Carcinoma, Squamous Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 109 open or running | phase 3since Jun 27, 2023 | Jun 27, 2023 | Apr 23, 2027phase 2 · NCT06305767 |
| Moderna | 22 open or running | phase 2since Mar 29, 2019 | Oct 13, 2017 | Nov 21, 2027phase 1 · NCT03313778 |
- Named in Merck’s own pipeline as
intismeran autogene (V940)
, phase 3, as of Nov 2, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentMerck develops it with Moderna, worldwide, costs and profits shared equally.Announced Oct 12, 2022 · Source: Merck, Oct 12, 2022
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.
- Oct 13, 2017First study: phase 1 study in Solid TumorsNew to ModernaModerna · NCT03313778 · 161 enrolled · United States, Australia, Japan and more
- Mar 29, 2019Phase 2 study in MelanomaModerna · NCT03897881 · 267 enrolled · United States, Australia
- Oct 12, 2022Merck develops it with ModernaCo-developmentWorldwide, costs and profits shared equally · announced · Merck
- Jun 27, 2023Merck's first study: phase 3 study in MelanomaNew to MerckMerck · NCT05933577 · 1,089 enrolled · United States, Argentina, Australia and more
- Oct 5, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT06077760 · 868 enrolled · United States, Argentina, Australia and more
- Feb 29, 2024Phase 3 study in Carcinoma, Squamous CellMerck · NCT06295809 · 46 enrolled · United States, Argentina, Australia and more
- Mar 5, 20242 phase 2 studiesMerck · NCT06305767, NCT06307431
- Sep 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT06623422 · 680 planned · United States, Argentina, Australia and more
- Feb 4, 2025Phase 2 study in Urinary Bladder NeoplasmsMerck · NCT06833073 · 308 planned · United States, Argentina, Australia and more
- Apr 29, 2025Phase 2 study in MelanomaMerck · NCT06961006 · 160 enrolled · United States, Australia, Canada and more
- Oct 24, 2025Phase 2 study in Squamous Non-small Cell Lung CancerMerck · NCT07221474 · 180 planned · United States, Argentina, Australia and more
- Apr 1, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT07513376 · 876 planned · United States, Australia, Brazil and more
Ahead
- Apr 23, 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT06305767
- Nov 21, 2027Primary completion: phase 1 study in Solid TumorsModerna · NCT03313778
- Jan 8, 2028Primary completion: phase 2 study in Carcinoma, Renal CellMerck · NCT06307431
- Jul 22, 2028Primary completion: phase 2 study in MelanomaMerck · NCT06961006
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting thirty-four tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells and encapsulated in lipid nanoparticles, with potential immunostimulatory and antineoplastic activities.…”NCIt, read by Claude
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07513376Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Recruiting | Merck | Aug 22, 2034 | 876 |
| NCT07221474Squamous Non-small Cell Lung Cancer · United States, Argentina, Australia and more | 2 | Recruiting | Merck | Jul 2, 2029 | 180 |
| NCT06961006Melanoma · United States, Australia, Canada and more | 2 | Active, not recruiting | Merck | Jul 22, 2028 | 160 |
| NCT06833073Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Merck | Sep 3, 2031 | 308 |
| NCT06623422Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Merck | May 16, 2033 | 680 |
| NCT06307431Carcinoma, Renal Cell · United States, Argentina, Australia and more | 2 | Active, not recruiting | Merck | Jan 8, 2028 | 272 |
| NCT06305767Urinary Bladder Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Merck | Apr 23, 2027 | 230 |
| NCT06295809Carcinoma, Squamous Cell · United States, Argentina, Australia and more | 3 | Terminated | Merck | Mar 5, 2026 | 46 |
| NCT06077760Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Jun 25, 2030 | 868 |
| NCT05933577Melanoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Oct 26, 2029 | 1,089 |
| NCT03897881Melanoma · United States, Australia | 2 | Active, not recruiting | Moderna | Nov 21, 2032 | 267 |
| NCT03313778Solid Tumors · United States, Australia, Japan and more | 1 | Active, not recruiting | Moderna | Nov 21, 2027 | 161 |
How it is read
Names in the registry
- “Intismeran autogene”, 8 entries
- “mRNA-4157”, 2 entries
- “Intismeran”, 1 entry
- “Intismeran Autogene”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Melanoma, 3 studies
- Non-Muscle Invasive Bladder Neoplasms, 1 study
- Carcinoma, Renal Cell, 1 study
- Carcinoma, Squamous Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.